ArticleJournal of oral and maxillofacial pathology : JOMFP
Diffuse large B-cell lymphoma: An immunohistochemical approach to diagnosis.
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Array comparative genomic hybridisation in haematological malignancies: A comprehensive review.African journal of laboratory medicine · 2026Review
- Microwave-Enhanced Synthesis of 2-Styrylquinoline-4-Carboxamides With Promising Anti-Lymphoma Activity.Archiv der Pharmazie · 2025Article
- Pediatric T-Cell/Histiocyte-Rich Large B-Cell Lymphoma (THRLBC) in an 8-Year-Old Male Child: A Case Report.Case reports in oncological medicine · 2025Article
- Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma.Frontiers in oncology · 2025Article
- Ki-67 as a Marker to Differentiate Burkitt Lymphoma and Diffuse Large B-cell Lymphoma: A Literature Review.Cureus · 2024Review
- Diffuse large B-cell lymphoma from duodenal with hematemesis, melena, and obstruction jaundice symptoms: A rare case.International journal of surgery case reports · 2023Article
- Expression of programmed cell death ligand-1 protein in germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.Molecular and clinical oncology · 2022Article
- It's Not Always Gynecomastia: A Case of Diffuse Large B-Cell Lymphoma Presenting as Breast Mass in a Male Patient.Cureus · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin's lymphoma (NHL) that develops from the B-cells of the lymphatic system. It is the most common subtype of NHL accounting for 30%-40% of all cases. In addition to determining if NHL is indolent or aggressive and whether it is B-cell, T-cell or NK-cell lymphoma, it is very important to determine the subtype of NHL. This is because each subtype can behave differently and may require different treatments. This warrants the need for an accurate and explicit subtype-specific diagnosis that catalogs the molecular prognostic indicators. Moreover, retrospective studies have confirmed that diagnosis to treatment interval is strongly associated with prognostic clinical factors and outcome in newly diagnosed cases of DLBCL. Therefore, an expeditious histological and immunohistochemical investigation should be compassed in cases of oral lymphomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.